AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10391813 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 69
Study 10391813 — intervention group
Group type: COMPARATOR
Intervention: Intradermal BCG vaccination
Number of subjects: 69
Study 8911354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple valve
Number of subjects: 70
Study 8911354 — intervention group
Group type: COMPARATOR
Intervention: Afferent tubular segment
Number of subjects: 70
Study 8911354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 1879394 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg)
Number of subjects: 31
Study 1879394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6128313 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 120
Study 6128313 — intervention group
Group type: EXPERIMENTAL
Intervention: Medazepam 10 mg
Number of subjects: 120
Study 6128313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30339299 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing task errors by moving the target mid-movement to align with cursor feedback of hand position
Number of subjects: 0
Study 30339299 — intervention group
Group type: COMPARATOR
Intervention: Enforcing task error by moving the target away from the cursor feedback of hand position by 20-30°
Number of subjects: 0
Study 27027671 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 43
Study 27027671 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 43
Study 27027671 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliation of symptoms with oxygen and morphine
Number of subjects: 43
Study 27027671 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comprehension of options
Number of subjects: 43
Study 27027671 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to wishes
Number of subjects: 43
Study 23362336 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 96
Study 23362336 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage plus guided imagery
Number of subjects: 96
Study 23362336 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 96
Study 23362336 — intervention group
Group type: COMPARATOR
Intervention: No‐treatment control
Number of subjects: 96
Study 22765260 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary fat/protein (CFP) counting
Number of subjects: 42
Study 22765260 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CARB) counting
Number of subjects: 42
Study 22765260 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal bolus with CFP counting
Number of subjects: 42
Study 22765260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-wave bolus with CFP counting
Number of subjects: 42
Study 22765260 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP counting
Number of subjects: 42
Study 20141275 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PD who were more aware of cue-reward relationships
Number of subjects: 0
Study 20141275 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally aware patients with PD
Number of subjects: 0
Study 20141275 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 18500678 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pioglitazone over nine days
Number of subjects: 18
Study 18500678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15598942 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 400 mg/m² for 1 year after surgery
Number of subjects: 332
Study 15598942 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 332
Study 15598942 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT for adenocarcinoma patients (n=120)
Number of subjects: 332
Study 15598942 — intervention group
Group type: COMPARATOR
Intervention: Control group for adenocarcinoma patients (n=121)
Number of subjects: 332
Study 15598942 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT for squamous cell carcinoma patients (n=43)
Number of subjects: 332
Study 15598942 — intervention group
Group type: COMPARATOR
Intervention: Control group for squamous cell carcinoma patients
Number of subjects: 332
Study 15598942 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT for all pT1 patients
Number of subjects: 332
Study 15598942 — intervention group
Group type: COMPARATOR
Intervention: Control group for all pT1 patients
Number of subjects: 332
Study 15598942 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT for pT1 adenocarcinoma patients
Number of subjects: 332
Study 15598942 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT for pT2 patients
Number of subjects: 332
Study 12027917 — intervention group
Group type: EXPERIMENTAL
Intervention: MOSES educational program
Number of subjects: 242
Study 9475816 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular team interventions involving a pharmacist, physician, nurses, undernurses, and nurse's aides discussing drug therapy.
Number of subjects: 15
Study 8584609 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg NNC 01-0687
Number of subjects: 0
Study 8584609 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg NNC 01-0687 administered t.i.d. for 14 days
Number of subjects: 0
Study 8584609 — intervention group
Group type: COMPARATOR
Intervention: NNC 01-0687 (active)
Number of subjects: 0
Study 8584609 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC 01-0687
Number of subjects: 0
Study 2223339 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 1.5 mg kg‐1 i.v. 1 min before laryngoscopy
Number of subjects: 45
Study 2223339 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 1.5 mg kg‐1 i.v. 2 min before laryngoscopy
Number of subjects: 45
Study 2223339 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 1.5 mg kg‐1 i.v. 3 min before laryngoscopy
Number of subjects: 45
Study 2223339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lignocaine)
Number of subjects: 45
Study 372525 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg/day)
Number of subjects: 0
Study 372525 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3.6 gm/day)
Number of subjects: 0
Study 372525 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 372525 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 31881545 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on clinical factor and biomarkers (degree of resection, E-cadherin, Ki-67, VEGFA)
Number of subjects: 201
Study 28535550 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage PRF
Number of subjects: 60
Study 28535550 — intervention group
Group type: COMPARATOR
Intervention: Standard voltage PRF
Number of subjects: 60
Study 25552421 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 25552421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study 24088361 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-IFN-α (9, 18, 27, and 36 MIU subcutaneous doses)
Number of subjects: 24
Study 21850272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GHRH (600 µg)
Number of subjects: 12
Study 21850272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19726914 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (stretching, muscle strengthening, and walking exercise)
Number of subjects: 21
Study 19726914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 21
Study 17596044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% carboxy‐methyl cellulose sodium paste containing 2% barium sulfate
Number of subjects: 107
Study 17596044 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5% potato starch containing 2% barium sulfate
Number of subjects: 107
Study 17596044 — intervention group
Group type: COMPARATOR
Intervention: 3% commercial barium paste
Number of subjects: 107
Study 14693410 — intervention group
Group type: EXPERIMENTAL
Intervention: InnoLet
Number of subjects: 79
Study 14693410 — intervention group
Group type: COMPARATOR
Intervention: vial/syringe
Number of subjects: 79
Study 11157327 — intervention group
Group type: COMPARATOR
Intervention: 1046 kJ energy load supplement
Number of subjects: 25
Study 11157327 — intervention group
Group type: COMPARATOR
Intervention: 2092 kJ energy load supplement
Number of subjects: 25
Study 11157327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich supplement (1046 kJ)
Number of subjects: 25
Study 11157327 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich supplement (1046 kJ)
Number of subjects: 25
Study 11157327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9640150 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia (EA) with lumbar extradural block and lidocaine (n = 11)
Number of subjects: 22
Study 9640150 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA) maintained with 1.5‐2.5% sevoflurane and 66% nitrous oxide in oxygen (n = 11)
Number of subjects: 22
Study 9640150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EA and GA)
Number of subjects: 22
Study 8092581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanesthesia using freon spray for venepuncture
Number of subjects: 80
Study 8092581 — intervention group
Group type: COMPARATOR
Intervention: Conventional venepuncture
Number of subjects: 80
Study 2663609 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon and insulin infusion (1 mg glucagon and 10 units insulin twice daily for one week)
Number of subjects: 98
Study 2663609 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 98
Study 22216499 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg theophylline orally
Number of subjects: 14
Study 22216499 — intervention group
Group type: COMPARATOR
Intervention: 200 microg salbutamol by pressurized aerosol
Number of subjects: 14
Study 22216499 — intervention group
Group type: EXPERIMENTAL
Intervention: theophylline
Number of subjects: 14
Study 31733754 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 120
Study 31733754 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 120
Study 31733754 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 28515105 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation testing using SHOX2 and SEPT9 DNA in plasma
Number of subjects: 649
Study 25976606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 120
Study 25976606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23661283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 19
Study 23661283 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (25 mg)
Number of subjects: 19
Study 23661283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 21740564 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week disease-related expressive writing procedure
Number of subjects: 0
Study 21740564 — intervention group
Group type: COMPARATOR
Intervention: Standard writing task (neutral writing condition)
Number of subjects: 0
Study 21740564 — intervention group
Group type: COMPARATOR
Intervention: Empty control condition
Number of subjects: 0
Study 21740564 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing condition (writing about facts regarding heart disease and its treatment)
Number of subjects: 0
Study 19302743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-angle group (bifurcation angle >= 60 degrees)
Number of subjects: 212
Study 19302743 — intervention group
Group type: COMPARATOR
Intervention: Low-angle group (bifurcation angle < 60 degrees)
Number of subjects: 212
Study 19302743 — intervention group
Group type: EXPERIMENTAL
Intervention: With-FKBI group (final kissing balloon inflation)
Number of subjects: 212
Study 19302743 — intervention group
Group type: COMPARATOR
Intervention: Without-FKBI group (no final kissing balloon inflation)
Number of subjects: 212
Study 19302743 — intervention group
Group type: COMPARATOR
Intervention: Without-FKBI group
Number of subjects: 212
Study 19302743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-angle group
Number of subjects: 212
Study 19302743 — intervention group
Group type: COMPARATOR
Intervention: Low-angle group
Number of subjects: 212
Study 17011781 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) insert
Number of subjects: 47
Study 17011781 — intervention group
Group type: COMPARATOR
Intervention: Concave insert
Number of subjects: 47
Study 17011781 — intervention group
Group type: COMPARATOR
Intervention: Flat insert
Number of subjects: 47
Study 14692296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional interventions for prevention of type 2 diabetes
Number of subjects: 0
Study 14692296 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 0
Study 14692296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional interventions
Number of subjects: 0
Study 10609980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 30
Study 10609980 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 30
Study 7634784 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent topical corticosteroid (betamethasone‐17‐valerate) applied 2x daily for 7 days
Number of subjects: 16
Study 7634784 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied 2x daily for 7 days
Number of subjects: 16
Study 1849392 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 22
Study 1849392 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 22
Study 6958486 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide given intranasally as an aerosol
Number of subjects: 22
Study 6958486 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) given as an aerosol
Number of subjects: 22
Study 6958486 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) given as a powder
Number of subjects: 22
Study 6539997 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cyclophosphamide 1 Gm/M2 each month for six months; cis-platinum 100 mg/M2 each month for four months; combination chemotherapy (CISCA) for one patient)
Number of subjects: 70
Study 6539997 — intervention group
Group type: COMPARATOR
Intervention: Expectant follow-up
Number of subjects: 70
Study 30077569 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg aflibercept
Number of subjects: 616
Study 30077569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 616
Study 30077569 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 616
Study 26722854 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (with or without hypothermia)
Number of subjects: 107
Study 24317704 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 92
Study 24317704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23362673 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (group 2)
Number of subjects: 3
Study 23362673 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical exercise (group 3)
Number of subjects: 3
Study 23362673 — intervention group
Group type: COMPARATOR
Intervention: Resting condition (group 1)
Number of subjects: 3
Study 20970079 — intervention group
Group type: EXPERIMENTAL
Intervention: REAL MEN intervention (30-hour jail/community-based intervention)
Number of subjects: 552
Study 20970079 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of CBO services
Number of subjects: 552
Study 20970079 — intervention group
Group type: EXPERIMENTAL
Intervention: REAL MEN intervention
Number of subjects: 552
Study 20970079 — intervention group
Group type: EXPERIMENTAL
Intervention: CBO visitors
Number of subjects: 552
Study 20970079 — intervention group
Group type: COMPARATOR
Intervention: All participants (including control)
Number of subjects: 552
Study 18564001 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for perfect breastfeeding
Number of subjects: 20
Study 18564001 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg/dose every 8 hours for 15 days)
Number of subjects: 20
Study 18564001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 15 days)
Number of subjects: 20
Study 16001749 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of misoprostol
Number of subjects: 95
Study 16001749 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of misoprostol
Number of subjects: 95
Study 12462537 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses
Number of subjects: 469
Study 12462537 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 469
Study 10683591 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7604668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 13
Study 2029409 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 195
Study 2029409 — intervention group
Group type: COMPARATOR
Intervention: diethylstilbestrol
Number of subjects: 195
Study 2029409 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA studies
Number of subjects: 195
Study 7032273 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms trivalent chromium in 5 ml water (Cr)
Number of subjects: 23
Study 7032273 — intervention group
Group type: COMPARATOR
Intervention: 5 ml plain water (W)
Number of subjects: 23
Study 30777903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency Ablation (C-RFA)
Number of subjects: 43
Study 30777903 — intervention group
Group type: COMPARATOR
Intervention: Traditional Radiofrequency Ablation (T-RFA)
Number of subjects: 43
Study 28720372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic lithotripsy
Number of subjects: 180
Study 28720372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic lithotripsy
Number of subjects: 180
Study 27101684 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI target biopsy
Number of subjects: 156
Study 27101684 — intervention group
Group type: COMPARATOR
Intervention: Regular biopsy
Number of subjects: 156
Study 24196948 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) with valproic acid
Number of subjects: 43
Study 24196948 — intervention group
Group type: COMPARATOR
Intervention: Single valproic acid
Number of subjects: 43
Study 22233788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low load exercises targeting the gluteal muscle group (GM-P)
Number of subjects: 22
Study 22233788 — intervention group
Group type: COMPARATOR
Intervention: Whole-body vibration protocol (WBV-P)
Number of subjects: 22
Study 22233788 — intervention group
Group type: COMPARATOR
Intervention: No-warm-up condition (CON)
Number of subjects: 22
Study 19772514 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nebulized glucocorticoid (400 microg beclomethasone bid) plus prn bronchodilator (2500 microg salbutamol)
Number of subjects: 276
Study 19772514 — intervention group
Group type: EXPERIMENTAL
Intervention: prn nebulized bronchodilator/glucocorticoid combination (800 microg beclomethasone/1600 microg salbutamol)
Number of subjects: 276
Study 19772514 — intervention group
Group type: COMPARATOR
Intervention: prn salbutamol (2500 microg)
Number of subjects: 276
Study 17504586 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model with facilitated self-help programme
Number of subjects: 105
Study 17504586 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 105
Study 15801580 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling program consisting of seven sessions over 6 months.
Number of subjects: 150
Study 15801580 — intervention group
Group type: COMPARATOR
Intervention: Measures-only control condition.
Number of subjects: 150
Study 12953084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium clodronate (2080 mg/day)
Number of subjects: 311
Study 12953084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 10052021 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of vitamin C (C)
Number of subjects: 56
Study 10052021 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 56
Study 7734260 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg kg‐1
Number of subjects: 80
Study 7734260 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg kg‐1
Number of subjects: 80
Study 7734260 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg kg‐1
Number of subjects: 80
Study 7734260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.3 mg kg‐1
Number of subjects: 80
Study 7734260 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.25 mg kg‐1 with Pyridostigmine 0.15 mg kg‐1
Number of subjects: 80
Study 7734260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 80
Study 7734260 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 80
Study 1682174 — intervention group
Group type: EXPERIMENTAL
Intervention: distigmine bromide
Number of subjects: 100
Study 1682174 — intervention group
Group type: EXPERIMENTAL
Intervention: prostaglandin F2 alpha
Number of subjects: 100
Study 1682174 — intervention group
Group type: EXPERIMENTAL
Intervention: phenoxybenzamine hydrochloride
Number of subjects: 100
Study 1682174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 6174864 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 44
Study 6174864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6174864 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose Human leukocyte interferon
Number of subjects: 44